CSL
Amplia (ASX:ATX) Adds Ovarian Trial with ANZGOG After Narmafotinib Hits 35% Pancreatic Response Rate
Amplia Adds Ovarian Trial After Pancreatic Success Amplia Therapeutics (ASX:ATX) has opened a new chapter in its drug story. On 8 May, the small-cap biotech announced a partnership with the Australia New Zealand Gynaecological Oncology Group (ANZGOG) to test its lead drug, narmafotinib, in ovarian cancer. The new study, called PRROSE, will treat patients with…
SKS Technologies
SKS Technologies (ASX:SKS) Hits Record High on Contract Win and CBA Boost: Buy the Breakout or Wait for a Pullback?
SKS Technologies Hits Record High on Contract Win SKS Technologies (ASX: SKS) hit a fresh record high on Friday, touching A$8.20 intraday before closing at A$8.04, up 6.5%. The move wasn't driven by one announcement but two: a A$22 million Buildcorp contract for a major retailer's new Melbourne Docklands headquarters and approval from Commonwealth Bank…
© 2026 Kicker. All Rights Reserved.

Add Your Heading Text Here